Healthcare Resource Use and Burden Associated with Influenza Transmission Among Household Members with a Primary Infection: Commercial Claims Data Analysis.

children claims household influenza observational retrospective

Journal

ClinicoEconomics and outcomes research : CEOR
ISSN: 1178-6981
Titre abrégé: Clinicoecon Outcomes Res
Pays: New Zealand
ID NLM: 101560564

Informations de publication

Date de publication:
2021
Historique:
received: 01 01 2021
accepted: 13 04 2021
entrez: 7 5 2021
pubmed: 8 5 2021
medline: 8 5 2021
Statut: epublish

Résumé

To assess the burden of influenza transmission and care-seeking patterns over 3 influenza seasons among commercially insured households with a primary influenza infection. This retrospective cohort study used commercial claims data from the US MarketScan Among 1,224,808 households with ≥2 members and a primary case of influenza, a secondary case of influenza was reported in 119,883 households (9.8%). A secondary diagnosed case of influenza occurred within 4 days of the primary diagnosis in 93,883 (78.3%) of those households. Both primary and secondary diagnosed influenza cases occurred most often among children (~60%). Household size was positively correlated to both the risk of a second case (6.4% of households with 2 or 3 members versus 12.6% of households with ≥4 members, Claims data for 3 influenza seasons (2014, 2015, 2016) showed that intrahousehold transmission of influenza occurs in approximately 10% of households with a primary case and poses a higher burden on larger households. Intrahousehold transmission of influenza represents a large healthcare resource use burden, with an unmet need for interventions that limit transmission.

Identifiants

pubmed: 33958880
doi: 10.2147/CEOR.S298992
pii: 298992
pmc: PMC8096342
doi:

Types de publication

Journal Article

Langues

eng

Pagination

335-342

Informations de copyright

© 2021 Wallick et al.

Déclaration de conflit d'intérêts

All authors are full-time employees of Genentech, Inc. and hold Genentech stock.

Références

J Infect Chemother. 2013 Aug;19(4):740-9
pubmed: 23732307
Br J Gen Pract. 2004 Sep;54(506):684-9
pubmed: 15353055
Am J Public Health. 1993 Dec;83(12):1712-6
pubmed: 8259800
Epidemiol Infect. 2017 Mar;145(4):723-727
pubmed: 27916020
PLoS Comput Biol. 2010 Jan 29;6(1):e1000656
pubmed: 20126529
PLoS One. 2012;7(2):e31519
pubmed: 22359599
N Engl J Med. 2020 Jul 23;383(4):309-320
pubmed: 32640124
CMAJ Open. 2016 Aug 22;4(3):E463-E470
pubmed: 27730110
Trends Microbiol. 2016 Feb;24(2):123-133
pubmed: 26612500
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677
Am J Prev Med. 2015 Apr;48(4):384-91
pubmed: 25700653
J Infect Dis. 2010 Apr 1;201(7):984-92
pubmed: 20187740
Hum Vaccin Immunother. 2017 Sep 2;13(9):2041-2047
pubmed: 28700268
Lancet Infect Dis. 2015 Jun;15(6):654-62
pubmed: 25788164
Hong Kong Med J. 2013 Jun;19 Suppl 4:19-23
pubmed: 23775182
N Engl J Med. 2010 Jun 10;362(23):2175-2184
pubmed: 20558368
PLoS Pathog. 2014 Aug 21;10(8):e1004310
pubmed: 25144780
Emerg Infect Dis. 2011 Jun;17(6):990-9
pubmed: 21749759
Epidemiology. 2012 Jul;23(4):531-42
pubmed: 22561117
N Engl J Med. 2009 Dec 31;361(27):2619-27
pubmed: 20042753
Clin Infect Dis. 2017 Mar 15;64(6):736-742
pubmed: 28011603
J Infect. 2014 Jun;68(6):581-90
pubmed: 24491598
Clin Infect Dis. 2010 Mar 1;50(5):707-14
pubmed: 20121573

Auteurs

Christopher Wallick (C)

Genentech, Inc, South San Francisco, CA, USA.

Ibrahim M Abbass (IM)

Genentech, Inc, South San Francisco, CA, USA.

Daniel Sheinson (D)

Genentech, Inc, South San Francisco, CA, USA.

Dalia Moawad (D)

Genentech, Inc, South San Francisco, CA, USA.

Classifications MeSH